PRA Health Sciences, Salt Lake City, Utah. ORCID: https://orcid.org/0000-0001-8609-9424.
PRA Health Sciences, Salt Lake City, Utah.
J Opioid Manag. 2022 Mar-Apr;18(2):181-190. doi: 10.5055/jom.2022.0708.
Evaluate the pupillary-constricting effects following administration of buprenorphine buccal film (BBF) and immediate-release (IR) oxycodone.
A double-blind, double-dummy, six-treatment, six-period, placebo-controlled, randomized crossover study.
Single-center, phase 1 exploratory pharmacodynamics.
Healthy individuals who self-identify as recreational opioid users, confirmed via a naloxone challenge test on day 1.
Placebo: BBF 300, 600, and 900 mcg and IR oxycodone 30 and 60 mg.
Minute ventilation (measured by the ventilatory response to hypercapnia) and pupil diameter (determined via standard pupillometry) were assessed predose and at 0.5, 1, 1.5, 2, 2.5, 3, and 4 hours post-dose.
Change from baseline in minute ventilation was moderately correlated with change from baseline in pupil diameter during treatment with BBF (Pearson's r = 0.38-0.40; p ≤ 0.0011) or oxycodone (Pearson's r = 0.34-0.37; p ≤ 0.005). The initial onset of significant (p < 0.05) pupil constriction relative to placebo occurred at 2, 1.5, and 1 hour after dosing with BBF 300, 600, and 900 mcg, respectively, and at 0.5 hours after dosing with oxycodone 30 or 60 mg.
Although BBF and IR oxycodone achieved similar levels of pupil constriction, there was a delayed miosis seen with BBF relative to that found with oxycodone.
评估丁丙诺啡颊膜(BBF)和即释(IR)羟考酮给药后的瞳孔收缩效应。
双盲、双模拟、六处理、六周期、安慰剂对照、随机交叉研究。
单中心、1 期探索性药效学研究。
自我认定为娱乐性阿片类药物使用者的健康个体,在第 1 天通过纳洛酮挑战测试确认。
安慰剂:BBF 300、600 和 900 mcg 以及 IR 羟考酮 30 和 60 mg。
分钟通气量(通过对高碳酸血症的通气反应测量)和瞳孔直径(通过标准瞳孔测量法确定)在给药前和给药后 0.5、1、1.5、2、2.5、3 和 4 小时进行评估。
BBF 治疗时,分钟通气量从基线的变化与瞳孔直径从基线的变化呈中度相关(Pearson r = 0.38-0.40;p ≤ 0.0011)或羟考酮(Pearson r = 0.34-0.37;p ≤ 0.005)。与安慰剂相比,BBF 300、600 和 900 mcg 分别在给药后 2、1.5 和 1 小时以及羟考酮 30 或 60 mg 给药后 0.5 小时出现显著(p < 0.05)瞳孔收缩的初始发生时间。
尽管 BBF 和 IR 羟考酮达到了相似水平的瞳孔收缩,但与羟考酮相比,BBF 出现了延迟性瞳孔缩小。